Kyle Doherty

Verzenio showed meaningful improvement for some patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 treatment: © stock.adobe.com.

Data from the retrospective rAMBER study, presented at the 

2025 San Antonio Breast Cancer Symposium(SABCS),

 showed that Verzenio (abemaciclib) monotherapy offered clinical benefit to some patients with hormone receptor (HR)–positive, HER2-negative breast cancer who had progressed on prior CDK4/6 inhibitor therapy.

The study evaluated how effective Verzenio could be when used alone after progression on previous CDK4/6 therapy, offering insight into the potential of sequential treatment in this patient population.

Approximately 33% of patients who received Verzenio across four academic centers (30 patients) derived meaningful clinical benefit from the therapy. Verzenio was generally well tolerated for more than 180 days, even in patients whose disease had progressed on prior Ibrance therapy and ongoing endocrine treatments. Most patients (23 of 30) continued on Verzenio until either disease progression or death, while the remaining 7 patients discontinued therapy due to side effects.

The median duration of treatment with Verzenio was 4 months following progression on Ibrance-based therapy, and the median number of intervening lines of therapy between Ibrance and Verzenio was 2, highlighting the potential of Verzenio to offer disease control even after multiple prior treatments.

“CDK4/6 inhibitors have become the standard of care for patients with advanced HR-positive, HER2-negative breast cancer. However, uncertainty remains regarding the efficacy of re-introducing CDK4/6 inhibitors after disease progression on prior therapy,” said Dr. Sahar Shahamatdar, an internal medicine resident at Massachusetts General Hospital, and her coauthors. “rAMBER is the first study to evaluate the effectiveness of Verzenio monotherapy in this setting, offering new insights into sequential CDK4/6 therapy and potential treatment strategies for patients who have exhausted standard options.”

Verzenio was approved by the U.S. Food and Drug Administration (FDA) in February 2018

 for use in combination with an aromatase inhibitor as a frontline therapy for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. This decision was supported by prior phase 3 MONARCH 3 data showing a median progression-free survival of 28.2 months with Verzenio versus 14.8 months for patients receiving placebo, confirming its efficacy in first-line settings.

The rAMBER study collected retrospective patient data from Massachusetts General Hospital, Barnes-Jewish Hospital, University of Pittsburgh Medical Center, and Moffitt Cancer Center. Patients with metastatic HR-positive, HER2-negative breast cancer who received Verzenio monotherapy after disease progression on a CDK4/6 inhibitor–based regimen were included. Patients were divided into two subgroups: sequential CDK4/6 therapy (6 patients) and nonsequential therapy (24 patients). Data were collected under Institutional Review Board–approved protocols, examining patient demographics, clinical outcomes, and treatment duration. Serial RECIST measurements were collected from imaging studies, and solid tumor and cell-free DNA were analyzed using targeted sequencing.

Each biopsy was assigned a phenotype based on the best clinical response and duration of response relative to biopsy timing, defined as sensitive, acquired resistant, or intrinsically resistant. One patient achieved a partial response with Verzenio, seven patients experienced stable disease, and eight experienced disease progression. Genomic analysis of 23 biopsies showed RB1 alterations were associated with acquired or intrinsic resistance, and ESR1 alterations were found across all biopsy phenotypes.

“Preliminary genetic analyses revealed enrichment in RB1 alterations in patients with rapid disease progression,” Shahamatdar and her coauthors concluded. These findings highlight the potential of Verzenio monotherapy to provide clinical benefit even after prior CDK4/6 inhibitor therapy and demonstrate the importance of understanding tumor genetics when considering sequential treatment strategies for advanced breast cancer.

“Updated analyses from the retrospective rAMBER study exploring abemaciclib after prior CDK4/6 inhibitor progression in metastatic hormone-receptor positive breast cancer,” by Dr. Sahar Shahamatdar, et al. Presented at: San Antonio Breast Cancer Symposium; December 9-12, 2025; San Antonio, TX. Abstract PS1-10-01.

“FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer,” by the U.S. FDA. News release; Feb. 26, 2018.

For more news on cancer updates, research and education, don’t forget to 

Articles

Verzenio (abemaciclib) monotherapy has shown clinical benefits for some patients with hormone receptor-positive, HER2-negative breast cancer who progressed on prior CDK4/6 inhibitor therapy, according to the rAMBER study. Approximately 33% of patients experienced meaningful benefits, with Verzenio generally well tolerated. The study highlights Verzenio's potential for disease control after multiple treatments. Genomic analysis revealed RB1 and ESR1 alterations linked to resistance. These findings underscore the importance of understanding tumor genetics in developing sequential treatment strategies for advanced breast cancer.

Verzenio showed meaningful improvement for some patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 treatment.

Verzenio Offers Potential Benefit After Prior Therapy in HR+/HER2– Breast Cancer

KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses in multiple myeloma.

In four patients with relapsed/refractory multiple myeloma, the investigational, 

 BCMA-directed CAR-T therapy–generating agent KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses, and the treatment had a favorable safety profile as an off-the-shelf product, clinical trial data have shown.

First-in-human results from the phase 1 inMMyCAR trial were presented during the 2025 ASH Annual Meeting.

Responses deepened over time, with patient 1 achieving a complete response at a MRD sensitivity level of 10

 after month 5; patient 2 achieving a partial response (PR) at a MRD sensitivity level of 10

during month 4; patient 3 achieving a PR at a MRD sensitivity level of 10

during month 3; and patient 4 achieving a PR at a MRD sensitivity level of 10

at the beginning of month 2. Of note, in the first two patients with the longest follow-up, MRD-negative bone marrow responses were sustained through three months.

Minimal residual disease (MRD): A very small number of cancer cells that remain in the body after treatment. These cells are too few to cause symptoms but can be detected with sensitive tests.

Complete response: All signs of cancer disappear after treatment. This does not always mean the cancer is cured, but no cancer can be found on tests.

Partial response: The cancer shrinks but does not go away completely.

Immune effector cell–associated neurotoxicity syndrome (ICANS): A temporary side effect that can occur after immune-based therapies (like CAR-T cells). It can cause confusion, trouble speaking, headaches or drowsiness.

Cytokine release syndrome (CRS): A reaction that happens when the immune system becomes very active during certain cancer treatments. It may cause fever, low blood pressure, or trouble breathing.

Infusion-related reaction (IRR): Symptoms such as fever, chills, rash or low blood pressure that can occur during or shortly after a medicine is given by infusion.

Lymphocytosis: A higher-than-normal number of lymphocytes (a type of white blood cell). Sometimes this happens as part of the body’s response to treatment.

Lymphopenia: A lower-than-normal number of lymphocytes, which may increase the risk of infection.

Neutropenia: A low level of neutrophils (another type of white blood cell), which increases infection risk.

Febrile neutropenia: A fever that occurs when neutrophil levels are very low. This is considered an emergency because it can signal a serious infection.

Anemia: A low red blood cell count. This can cause tiredness, shortness of breath, or dizziness.

Thrombocytopenia: A low platelet count. Platelets are needed for blood clotting, so low levels may lead to easy bruising or bleeding.

Hypomagnesemia: Low magnesium levels in the blood. This may cause muscle cramps, weakness, or abnormal heart rhythms.

Hypokalemia: Low potassium levels in the blood. Symptoms may include fatigue, muscle weakness, or irregular heartbeat.

Vasovagal syncope: A brief fainting episode caused by a sudden drop in heart rate and blood pressure, often triggered by pain, stress, or medical procedures.

CAR-T cell expansion occurred despite the absence of lymphodepleting chemotherapy. All patients experienced a rise in lymphocyte count. Dexamethasone was administered to patients 3 and 4 with prompt resolution and no clinical sequelae. Additionally, CAR-positive T cells were detected in the blood at day 15 at rates of 35%, 22%, 72% and 85%, and comprised a mixture of CD4 and CD8 CAR T-cells. Of note, the highest level of CAR-positive cells was achieved at dose level –1.

“These initial MRD-negative responses and persistent CAR-T cell [expansion may be] prognostic of ongoing clinical responses,” presenting author Phoebe Joy Ho, a professor at the University of Sydney, shared. “Establishing durability of response [DOR] remains a priority in continued follow-up, and updated results will be presented at future meetings.”

Ho is also a senior staff specialist in hematology, the director of research, and head of the Multiple Myeloma Research Unit and Thalassemia/Haemoglobinopathy Unit at the Institute of Haematology, Royal Prince Alfred Hospital in Sydney, Australia.

Why was KLN-1010 chosen for investigation in this patient population, and what makes its mechanism of action unique?

KLN‑1010 is an envelope-modified, replication-incompetent, self-inactivating modified lentiviral vector gene therapy administered intravenously to generate novel, fully-human anti-BCMA CAR-T cells in vivo. Designed as an off-the-shelf therapy, KLN-1010 eliminates the need for preconditioning lymphodepleting chemotherapy, simplifies the logistics of CAR-T cell administration, and may increase T-cell fitness through the absence of ex vivo culture, all of which could improve access to CAR-T cell therapies, Ho explained.

inMMyCAR is a first-in-human, dose-escalation/-expansion study conducted at three different sites in Australia: Peter MacCallum Cancer Center, The Alfred Hospital and Royal Prince Alfred Hospital. The study plans to enroll approximately 20 patients with relapsed/refractory multiple myeloma who received three or more lines of prior therapy, including a proteasome inhibitor (PI), immunomodulatory drug (IMiD) or anti-CD38 antibodies. Other eligibility criteria include an ECOG performance status of 0 or 1 and adequate bone marrow or organ function.

The ages of patients 1, 2, 3 and 4 were 72 years, 62 years, 61 years and 70 years, respectively. Patients 1 and 4 were male; patients 2 and 3 were female. These patients received 4, 3, 3 and 5 prior lines of therapy, respectively. Patients 1, 3, and 4 were all refractory to PIs, IMiDs, and anti-CD38 antibodies; patient 2 was only refractory to IMiDs and anti-CD38 antibodies. No patients had extramedullary disease and all patients had previously undergone autologous stem cell transplant.

What should be known about the agent’s safety profile?

Investigators did not observe any instances of immune effector cell–associated neurotoxicity syndrome or delayed neurotoxicity. Moreover, all cases of cytokine release syndrome (CRS) were low-grade, and CRS events were consistent with those seen with 

CAR-T cell therapies. The median onset of CRS was 10 days, and the median duration was 5.5 days. Two Grade 1 (mild)/2 (moderate) CRS events occurred at dose level 1, and 1 grade 1/2 CRS event occurred at dose level –1. Dexamethasone and Actemra (tocilizumab) were administered as supportive care measures (three patients each).

Treatment-emergent side effects that occurred in more than one patient included Infusion-related reactions (IRR; grade 1/2, two patients; grade 3 (severe) or higher, one patient [dose-limiting toxicity]), lymphocytosis (one patient each), hypomagnesemia (two and zero patients), and hypokalemia (two and zero patients). Grade 3 or higher treatment-emergent side effects included febrile neutropenia, IRR, lymphopenia, lymphocytosis, anemia, vasovagal syncope and pneumonia (one patient each).

Cytopenias were also minimal, with only one case of grade 4 (life-threatening) transient neutropenia reported. Grade 3 or higher anemia and thrombocytopenia occurred in one patient each on study days 15 and 16, respectively, and lasted for two days. Two patients experienced grade 3 or higher neutropenia. One grade 1/2 and one grade 3 or higher IRR occurred at dose level 1; tocilizumab and steroids were administered as supportive care. One grade 1/2 IRR occurred at dose level –1, and paracetamol was administered as supportive care.

This favorable safety and tolerability profile, which was achieved with an off-the-shelf product, suggests that outpatient administration of KLN-1010 may be feasible, Ho concluded.

“Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010: results of a phase 2 trial” by Phoebe Joy Ho et al., 

For more news on cancer updates, research and education, don’t forget to

KLN-1010, an investigational BCMA-directed CAR-T therapy, demonstrated promising MRD-negative responses in patients with relapsed/refractory multiple myeloma, with a favorable safety profile. The phase 1 inMMyCAR trial showed deepening responses over time, with sustained MRD-negative bone marrow responses in patients with longer follow-up. The therapy, administered without lymphodepleting chemotherapy, resulted in CAR-T cell expansion and manageable side effects. KLN-1010's unique mechanism simplifies CAR-T administration and may enhance T-cell fitness, potentially improving access to CAR-T therapies for multiple myeloma patients.

Off-The-Shelf CAR-T KLN-1010 Associated With Deep Responses in R/R Myeloma

Eflornithine plus Gleostine was associated with superior overall survival and progression-free survival in grade 3 IDH-mutated astrocytoma.

Among patients with recurrent grade 3 IDH-mutated astrocytoma, 

he addition of eflornithine to Gleostine (lomustine) was associated with clinically meaningful overall survival (OS) and progression-free survival (PFS) benefits when compared with treatment via Gleostine alone, study results have shown.

Updated data from the phase 3 STELLAR study were presented during the 2025 Society of Neuro-Oncology Annual Meeting.

In the updated analysis, investigators reclassified patients from the original intention-to-treat (ITT) population (343 patients) using updated molecular classification to identify a subset of patients (57%) who had grade 3/4, IDH-mutated astrocytoma.

Progression-Free Survival (PFS): This measures how long a patient lives without their cancer getting worse (progressing).

Overall Survival (OS): The length of time from the start of diagnosis or treatment until a patient dies.

Karnofsky Performance Status (KPS): This is a score (from 0 to 100) that doctors use to measure a patient's general well-being and their ability to perform daily activities.

Myelosuppression: This is a side effect where a treatment, like chemotherapy or radiation, slows down or stops the production of new blood cells in the bone marrow (the soft tissue inside your bones).

Patients with grade 3 or 4 disease who received the combination (116 patients) achieved a median OS of 28.5 months compared with 22.3 months among those who received Gleostine monotherapy (119 patients). The median PFS values were 12.3 months and 7.3 months, respectively. Additionally, findings from a blinded independent central MRI review of PFS among patients with grade 3 disease revealed that the PFS benefit with eflornithine was consistent with the investigator-assessed PFS benefit.

“This updated classification based on [World Health Organization] 2021 [criteria] of the STELLAR population confirms the benefit of eflornithine in grade 3, IDH-mutant, CDK-intact population,” Dr. Howard Colman explained during the presentation. “The blinded independent review of the MRI results confirms the PFS benefit observed by investigators and the high correlation between the effect of PFS and OS in this subgroup. This is the first demonstration of a clinically significant OS and PFS benefit in a randomized study in this population.”

Colman is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team and the leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.

STELLAR was an open-label study that enrolled patients a surgical or biopsy-proven diagnosis of WHO grade 3 anaplastic astrocytoma. Patients were also required to have experienced their first instance of disease progression or recurrence at least six months after the completion of external beam radiation therapy (ERBT). Prior treatment with ERBT and Temodar (temozolomide) plus chemotherapy prior to the first instance of disease progression or recurrence was required, as was a Karnofsky Performance Status (KPS) of at least 70 and adequate organ function.

“The STELLAR trial started in 2016 under the prior WHO diagnostic criteria, [and] this created several difficulties, but [an] extensive effort was made to gather historical archival tissue to reclassify the population based on 2021 WHO criteria,” Colman explained.

Patients were randomly assigned to receive eflornithine plus Gleostine (arm A) or Gleostine monotherapy (arm B). Patients in arm A received eflornithine at 2.8 g/m

 on a two-weeks-on, one-week-off schedule for up to 24 months in combination with Gleostine at 90 mg/m

 once on day 15 and once every six weeks during the eflornithine off weeks for up to six cycles or 12 months, whichever came first. Patients in arm B received Gleostine at 100 mg/m

 once every six weeks for up to six cycles or 12 months, whichever came first.

At baseline, the median age in the ITT population (343 patients) was 43 years. Most patients were 45 years old or younger (56%), male (60.9%), underwent one or two surgical resections (86%), and had a KPS of at least 90 (68.0%). The median time from the last dose of radiation therapy to random assignment was 26.6 months.

Previously reported data for the ITT population showed that patients treated with the combination (172 patients) achieved a median OS of 23.4 months versus 20.3 months for those given Gleostine alone (171 patients). The median PFS was 8.9 months versus 7.2 months, respectively.

What was the safety profile of the combination?

In terms of safety, patients in the combination arm experienced grade 3 (severe) or higher treatment-emergent side effects related to eflornithine or Gleostine at respective rates of 50.9% and 45.6%. Grade 3 or higher treatment-emergent side effects of relevance were reported at a rate of 63.9% and included myelosuppression (39.6%), hearing loss (23.7%) and diarrhea (9.5%). Serious treatment-emergent side effects related to eflornithine or Gleostine were reported at rates of 7.7% and 3.6%, respectively.

In the monotherapy arm, grade 3 or higher treatment-emergent side effects related to Gleostine occurred in 33.3% of patients. Grade 3 or higher TEAEs of relevance (30%) included myelosuppression (28.7%), seizure (1.3%) and nausea (0.7%). Serious treatment-emergent side effects related to study treatment were also reported (2.7%).

“[The] toxicities were consistent with prior eflornithine; gastrointestinal [side effects] and decreased hearing were the notable toxicities,” Colman said.

“Updated results of phase 3 STELLAR trial: eflornithine improves overall survival and blinded independent central review determined progression free survival in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma” by Dr. Howard Colman et al. Presented at: 2025 SNO Annual Meeting; November 19-23, 2025; Honolulu, HI. Abstract CTNI-58.

“Study to evaluate eflornithine + lomustine vs lomustine in recurrent anaplastic astrocytoma (AA) patients (STELLAR);” https://clinicaltrials.gov/study/NCT02796261

For more news on cancer updates, research and education, 

don’t forget to subscribe to CURE®’s newsletters here.

The addition of eflornithine to Gleostine in patients with recurrent grade 3 IDH-mutated astrocytoma demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) compared to Gleostine alone. The phase 3 STELLAR study reclassified patients using updated molecular criteria, confirming the benefits of eflornithine in this subgroup. The combination therapy showed a median OS of 28.5 months versus 22.3 months for monotherapy. Safety profiles indicated higher rates of severe side effects with the combination, including myelosuppression and hearing loss, consistent with known eflornithine toxicities.

Eflornithine Plus Gleostine Improves Progression, Survival In Some With Astrocytoma

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations.

Among patents with IDH1- or IDH2-mutant glioma, the treatment combination of Voranigo (vorasidenib) plus Temodar (temozolomide) did not lead to any serious side effects or dose-limiting toxicities (DLTs), clinical trial results have shown.

Data from the phase 1b IDHEAL-4U trial were presented at the 2025 Society for Neuro-Oncology Annual Meeting.

Findings demonstrated that, with a median treatment duration 5.5 months, all patients (seven patients) experienced any-grade treatment-emergent side effects; 28.6% (two patients) had grade 3 (severe) or higher treatment-emergent side effects, which included decreased neutrophil count (14.3%) and decreased platelet count (28.6%). No patients discontinued treatment due to treatment-emergent side effects, and all patients completed the DLT evaluation portion of the study. As of the Sept. 8, 2025, data cutoff, 85.7% (six patients) remained on treatment with both study drugs.

Increased alanine aminotransferase (ALT) levels: 

ALT is an enzyme found mostly in the liver. When ALT levels are higher than normal on a blood test, it can be a sign that the liver is irritated or damaged. 


The Karnofsky performance status is a score doctors use to describe how well a person with cancer is able to carry out daily activities. The scale goes from 0 to 100. A higher number means the person is more active and able to care for themselves; a lower number means they need more help. 

Treatment-emergent side effects led to dose reductions in 42.9% of patients; notably, 14.3% required dose reductions of only Voranigo, 28.6% needed dose reductions of only Temodar, and no patients required dose reductions of both agents. Dose reductions of Voranigo stemmed from increased alanine aminotransferase (ALT) levels (14.3%), and reductions of Temodar were due to decreased platelet count (28.6%) and decreased neutrophil count (14.3%).

Treatment-emergent side effects required study drug interruption in 57.1% of patients, including 28.6% who needed dose interruptions of both treatments, which was due to increased ALT levels (28.6%). Only Voranigo was interrupted in 14.3% of patients, and only Temodar was interrupted in 57.1% of patients. Treatment-emergent side effects leading to dose interruptions of only Voranigo included increased ALT levels (14.3%), and these included neutropenia (42.9%) and decreased platelet count (42.9%) for Temodar only.

“Based on data from the May 6, 2025, data cutoff, the safety review committee declared [Voranigo at] 40 mg as the recommended combination dose [RCD] to be given in combination with standard-of-care [Temodar],” lead study author Dr. Macarena de la Fuente and colleagues wrote in a poster presentation of the data.

de la Fuente is an associate professor of neuro-oncology, chief of the Neuro-Oncology Division, clinical service leader for Neuro-Oncology Service Line - Sylvester Comprehensive Cancer Center, chair of the Neuro-Oncology Site Disease Group, director of the Neuro-Oncology Fellowship Program, and oncology clinical service leader for Neuro-Oncology at the Miller School of Medicine of University of Miami in Florida.

Why are Voranigo and Temodar being evaluated as a combination strategy in 

Although Voranigo is approved by the FDA for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection, treatment with IDH inhibitor monotherapy is unlikely to lead to disease control in patients with higher-grade, more aggressive gliomas.

As such, de la Fuente and colleagues hypothesized that adding Voranigo to Temodar could, “exploit the molecular vulnerabilities of higher-grade [IDH1/2-mutant] gliomas while controlling more rapidly proliferative tumor cells.”

IDHEAL-4U is a multicenter phase 1b/2 trial designed to evaluate the combination, with phase 1b focusing on safety, and the ongoing phase 2 portion looking at preliminary efficacy, safety, and tolerability for the RCD in patients with grade 4 astrocytoma harboring IDH1/2 mutations.

In phase 1b, investigators enrolled patients at least 12 years of age with grade 2 to 4 gliomas with IDH1/2 mutations who were eligible for Temodar in the adjuvant setting after radiotherapy or at first disease recurrence.

Voranigo was first evaluated at 40 mg once per day in combination with Temodar at 150 mg/m

 in cycles 2 to 12. Voranigo was continued until disease progression. After safety review committee input and analysis of DLT rate and BOIN design, investigators could dose de-escalate to evaluate Voranigo to 20 mg per day, or declare the RCD.

What were the patient characteristics in phase 1b?

The seven enrolled patients had a median age of 36 years, and 57.1% were female. Karnofsky performance status at baseline included 100 (14.3%), 90 (57.1%), 80 (14.3%) and 70 (14.3%). Patient tumor types included frontline grade 3 astrocytoma (42.9%), frontline grade 4 astrocytoma (14.3%), recurrent grade 4 astrocytoma (14.3%), frontline grade 3 oligodendroglioma (14.3%) and recurrent grade 4 oligodendroglioma (14.3%).

All patients had received prior radiation therapy. Three patients (42.9%) received prior systemic therapy, which was exclusively Temodar.

“Phase 1b safety results of vorasidenib in combination with temozolomide in patients with mutant IDH1 or IDH2 glioma” by Dr. Macarena de la Fuente et al., presented at: 2025 SNO Annual Meeting; November 19-23, 2025; Honolulu, HI. Abstract CTNI-34.

The combination of Voranigo and Temodar in IDH1/2-mutant glioma patients showed no serious side effects or dose-limiting toxicities in a phase 1b trial. All patients experienced treatment-emergent side effects, with 28.6% experiencing severe side effects. Dose reductions were necessary for 42.9% of patients, primarily due to increased ALT levels and decreased blood counts. The recommended combination dose for Voranigo was established at 40 mg. The trial aims to exploit molecular vulnerabilities in higher-grade gliomas, with ongoing evaluation of efficacy, safety, and tolerability in phase 2.

Kyle Doherty

Verzenio Offers Potential Benefit After Prior Therapy in HR+/HER2– Breast Cancer

Off-The-Shelf CAR-T KLN-1010 Associated With Deep Responses in R/R Myeloma

Eflornithine Plus Gleostine Improves Progression, Survival In Some With Astrocytoma

Voranigo Plus Temodar Found to Be Safe in Patients With IDH1/2+ Glioma

Latest News